Peripheral Immune-Inflammatory Pathways in Major Depressive Disorder, Bipolar Disorder, and Schizophrenia: Exploring Their Potential as Treatment Targets

Abbas F. Almulla; Michael Maes

doi:10.1007/s40263-025-01195-3

Back

Peripheral Immune-Inflammatory Pathways in Major Depressive Disorder, Bipolar Disorder, and Schizophrenia: Exploring Their Potential as Treatment Targets

Article 2025 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2022

Adjunctive minocycline for major depressive disorder: A sub-study exploring peripheral immune-inflammatory markers and associated treatment response

Adam J. Walker, Mohammadreza Mohebbi, Michael Maes, Michael Berk, Ken Walder, Chiara C. Bortolasci, Zoe Liu, Chee H. Ng, Melanie M. Ashton, Lesley Berk, Ajeet Singh, Gin S. Malhi, Olivia Dean

Article2018

Major Differences in Neurooxidative and Neuronitrosative Stress Pathways Between Major Depressive Disorder and Types I and II Bipolar Disorder

Michael Maes, Kamila Landucci Bonifácio, Nayara Rampazzo Morelli, Heber Odebrecht Vargas, Décio Sabbatini Barbosa, André F. Carvalho, Sandra Odebrecht Vargas Nunes

Preprint2022

Effects of cannabidiol on activated immune-inflammatory pathways in major depressive patients and healthy controls

Muanpetch Rachayon, Ketsupar Jirakran, Pimpayao Sodsai, Siriwan Klinchanhom, Atapol Sughondhabirom, Kitiporn Plaimas, Apichat Suratanee, Michael Maes

Article2012

Improving criteria for differentiating bipolar disorder and major depressive disorder in patients experiencing a major depressive episode

C. Bowden, Jules Angst, Azorin Jm, Eduard Vieta, Alex Gamma, Allan H. Young

Article2025

Neuroimmune, metabolic and oxidative stress pathways in major depressive disorder

Michael Maes, Abbas F. Almulla, Zili You, Yingqian Zhang